Virtual ACC 2020 | POPULAR TAVR: Post TAVR Anticoagulation without Clopidogrel?

In patients undergoing transcatheter aortic valve replacement (TAVR) that also required anticoagulation for another indication (mostly atrial fibrillation), the incidence of major bleeding between month 1 and 12 was lower in those receiving only anticoagulation instead of anticoagulation + clopidogrel. 

ACC 2020 Virtual | POPULAR TAVI: ¿anticoagulación sin clopidogrel post TAVI?

The present study presented as part of the scientific sessions at the virtual ACC 2020, simultaneously published in NEJM included TAVR patients with prior anticoagulation adequately indicated. Patients were randomized 1:1 to no clopidogrel (only anticoagulation) vs clopidogrel and anticoagulation for 3 months.

Primary end points were all bleedings not related to the procedure at 12 months. Secondary end points were a combination of cardiovascular death, bleeding not related to the procedure, stroke and MI.

Bleeding events occurred in 21.7% (34 of 157) of those receiving only anticoagulation vs 34.6% (54 of 156) of those receiving anticoagulation plus clopidogrel (RR 0.63; IC 95% 0.43 to 0.90; p=0.01). Most bleeding events were at the access site.


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


Bleeding events not related to the procedure occurred in 21.7% vs 34%, respectively (RR 0.64; CI 95% 0.44 to 0.92; p=0.02). Most bleeding events occurred in the first month and were minor. 

Conclusion

In TAVR patients with prior anticoagulation indication a strategy with no antiplatelet antiaggregation (clopidogrel) and only anticoagulation resulted safer.

populartavi

Original Title: Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.

Reference: V.J. Nijenhuis et al. NEJM 2020, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...